Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9181200 | BRISTOL | Pyrimidinedione compounds |
Jun, 2034
(11 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9585883 | BRISTOL | Pyrimidinedione compounds |
Jun, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Apr 28, 2029 |
New Chemical Entity Exclusivity (NCE) | Apr 28, 2027 |
NCE-1 date: 2026-04-28
Market Authorisation Date: 28 April, 2022
Treatment: Treatment of adults with symptomatic new york heart association (nyha) class ii-iii obstructive hypertrophic cardiomyopathy (hcm) to improve functional capacity and symptoms
Dosage: CAPSULE;ORAL
12
United States
4
Australia
3
Japan
3
Korea, Republic of
3
Israel
2
China
2
Singapore
2
EA
2
European Union
1
Spain
1
Hong Kong
1
Dominican Republic
1
Philippines
1
Malaysia
1
Denmark
1
RS
1
Poland
1
Brazil
1
Canada
1
Ukraine
1
Morocco
1
New Zealand
1
Croatia
1
Guatemala
1
Peru
1
Chile
1
Portugal
1
Mexico
1
Costa Rica
1
South Africa
1
Lithuania
1
Tunisia
1
Slovenia
1
Hungary
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic